Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Obesity Weight Loss, Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/7/2019 |
| Start Date: | October 5, 2018 |
| End Date: | March 19, 2021 |
Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
This study will look at the change in body weight from the start to the end of the study.
Researchers will compare the weight loss in people taking semaglutide (a new medicine) to
people taking "dummy" medicine. In addition to taking the medicine, participants will also
have talks with study staff about healthy food choices, how the participant can be more
physically active and what participants can do to lose weight. Participants will either get
semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance.
Participants will need to take 1 injection once a week. The study medicine is injected with a
thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about
2 years. The participants will have 19 clinic visits and 15 phone calls with the study
doctor.
Researchers will compare the weight loss in people taking semaglutide (a new medicine) to
people taking "dummy" medicine. In addition to taking the medicine, participants will also
have talks with study staff about healthy food choices, how the participant can be more
physically active and what participants can do to lose weight. Participants will either get
semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance.
Participants will need to take 1 injection once a week. The study medicine is injected with a
thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about
2 years. The participants will have 19 clinic visits and 15 phone calls with the study
doctor.
Inclusion Criteria:
- Male or female, age more than or equal to 18 years at the time of signing informed
consent
- Body mass index (BMI) more than or equal to 30 kg/m^2 or more than or equal to 27
kg/m^2 with the presence of at least one of the following weight-related comorbidities
(treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or
cardiovascular disease
- History of at least one self-reported unsuccessful dietary effort to lose body weight
Exclusion criteria:
- HbA1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory
at screening
- A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before
screening irrespective of medical records
We found this trial at
16
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials